 A pilot study has been conducted in subjects with advanced HCC with portal vein invasion for which effective therapeutic methods have not been established. This was a single-center, open-label study of localized concurrent chemoradiation therapy CCRT for locally advanced HCC patients with portal vein invasion. A total of 40 subjects with advanced HCC with portal vein invasion were enrolled. The subjects were treated with a total of 45 Gy of external beam radiotherapy 1.8 Gy per session, 5 sessions a week, for 5 weeks, with hepatic arterial infusion of 5-flourouracil 5-FU during the first and last 5 days of radiation therapy 5-FU 500 mg infusion for 5 hours through the pre-inserted chemoport. Eighteen 45 subjects had an objective tumor response at 1 month after completion of localized CCRT. The 3-year survival rate was 24.2 and median overall survival was 13.1 months. 